SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000891293-18-000055
Filing Date
2018-05-03
Accepted
2018-05-03 17:01:13
Documents
40
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cti10q03312018.htm 10-Q 757756
2 EXHIBIT 31.1 ex311-ceo302.htm EX-31.1 10994
3 EXHIBIT 31.2 ex312-cfo302.htm EX-31.2 12119
4 EXHIBIT 32 ex32-ceocfo906.htm EX-32 11882
  Complete submission text file 0000891293-18-000055.txt   2778879

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT ctic-20180331.xml EX-101.INS 308047
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20180331.xsd EX-101.SCH 20195
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20180331_cal.xml EX-101.CAL 56694
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20180331_def.xml EX-101.DEF 106490
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20180331_lab.xml EX-101.LAB 342258
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20180331_pre.xml EX-101.PRE 188705
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-28386 | Film No.: 18804753
SIC: 2834 Pharmaceutical Preparations